Dyno Therapeutics

Senior Director, Program Management

Waltham, Massachusetts, United States

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

The Senior Director, Program Management requires a Bachelor’s degree in a related field, along with 10+ years of experience in program management, preferably in the pharmaceutical or biotechnology industry. Strong leadership and influencing skills are essential, as is the ability to work effectively in a cross-functional matrix environment. Experience with drug development programs and a deep understanding of the rare disease space are highly desirable.

Responsibilities

This role involves leading cross-functional teams to drive the execution of drug development programs, facilitating strategic discussions, developing and maintaining program strategy documents such as the Target Product Profile and Clinical Development Plan, ensuring alignment of non-clinical, clinical, regulatory, and commercial strategies, and optimizing for quality, speed, and cost. The Senior Director will also be responsible for creating and maintaining detailed cross-functional plans, inspiring efficient plans to achieve development strategy, and accountable for the overall success of the program.

Skills

Program Management
Cross-functional Collaboration
Project Planning
Risk Management
Agile Methodology
Drug Development
Stakeholder Engagement

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Key Metrics

Watertown, MassachusettsHeadquarters
2018Year Founded
$106MTotal Funding
SERIES_ACompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.
Manufacturing bottlenecks could hinder scaling of Dyno's operations.
Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.
Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.
Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.
Collaboration with NVIDIA enhances biological sequence design for gene therapies.
Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI